Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2006-05-16
2006-05-16
Weddington, Kevin E. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C514S564000, C514S673000, C514S674000
Reexamination Certificate
active
07045550
ABSTRACT:
Polyamine effectors are administered locally to provide protection against the adverse side-effects of chemotherapy or radiation therapy, such as alopecia, mucositis and dermatitis. Pharmaceutical preparations comprising one or more polyamine effectors formulated for topical or local delivery to epithelial or mucosal cells are disclosed. Methods of administering the pharmaceutical preparations are also disclosed.
REFERENCES:
patent: 4720489 (1988-01-01), Shander
patent: 4935449 (1990-06-01), Bey et al.
patent: 4996057 (1991-02-01), Schoeff et al.
patent: 5091576 (1992-02-01), Bergeron
patent: 5109024 (1992-04-01), Prakash et al.
patent: 5137888 (1992-08-01), Bazzano
patent: 5217964 (1993-06-01), Edwards et al.
patent: 5354782 (1994-10-01), Edwards et al.
patent: 5434135 (1995-07-01), Parikh et al.
patent: 5434145 (1995-07-01), Edwards et al.
patent: 5648355 (1997-07-01), Theoharides
patent: 5654484 (1997-08-01), Prakash et al.
patent: 5677350 (1997-10-01), Frydman
patent: 5679682 (1997-10-01), Bergeron
patent: 5681837 (1997-10-01), Bergeron
patent: 5735263 (1998-04-01), Rubsamen et al.
patent: 5753714 (1998-05-01), Stemerick et al.
patent: 5827894 (1998-10-01), Bergeron
patent: 5843959 (1998-12-01), Bergeron, Jr.
patent: 5866613 (1999-02-01), Bergeron
patent: 5889061 (1999-03-01), Frydman et al.
patent: 5994339 (1999-11-01), Crapo et al.
patent: 6030948 (2000-02-01), Mann
patent: 6034139 (2000-03-01), Bergeron
patent: 6114394 (2000-09-01), Edwards et al.
patent: 6147262 (2000-11-01), Bergeron
patent: 6172261 (2001-01-01), Vermeulin et al.
patent: 6174261 (2001-01-01), Watanabe et al.
patent: 6239119 (2001-05-01), Stogniew et al.
patent: 6573290 (2003-06-01), Love
patent: 2002/0019338 (2002-02-01), Hebert
patent: 0 162 413 (1985-11-01), None
patent: 0 270 349 (1988-06-01), None
patent: 0 277 635 (1988-08-01), None
patent: 0 311 068 (1989-04-01), None
patent: 0 686 142 (1995-12-01), None
patent: 0 884 046 (1998-12-01), None
patent: 1 085 011 (2001-03-01), None
patent: 2000-327537 (2000-11-01), None
patent: WO 93/18760 (1993-03-01), None
patent: WO 94/07480 (1994-04-01), None
patent: WO 94/19311 (1994-09-01), None
patent: WO 96/23490 (1996-08-01), None
patent: WO 99/51213 (1999-10-01), None
patent: WO 00/05186 (2000-02-01), None
patent: WO 00/16763 (2000-03-01), None
patent: WO 00/46187 (2000-08-01), None
patent: WO 00/66587 (2000-11-01), None
patent: WO 00/78289 (2000-12-01), None
patent: WO 01/14464 (2001-03-01), None
patent: WO 01/72685 (2001-10-01), None
patent: WO 02/38105 (2002-05-01), None
Aphramaian, M., et al., “Transmucosal passage of polyalkylcyanoacrylate nanocapsules as a new drug carrier in the small intestine,”Biol. Cell, 1987, 61, 69-76.
Basu, H.S., et al., “The interaction of spermine and petamines with DNA,”Biochem J., 1987, 244, 243-246.
Basu, H.S., et al., “Effects of variation in the structure of spermine on the association with DNA and the induction of DNA conformational changes,”Biochem. J., 1990, 269, 329-334.
Basu, H.S., et al., “Correlation between the effects of polyamine analogues on DNA conformation and cell growth, ”Cancer Res.,1989, 49, 5591-5597.
Basu, H.S., et al., “Interaction of a polyamine analogue, 1,19-bis-(Ethylamino)- 5,10,15-triazanonadecane (BE-4-4-4-4), with DNA and effect on growth, survival, and polyamine levels in seven human brain tumor cell lines,”Cancer Res., 1993, 53, 3948-3955.
Bergeron, C.J., et al., “Two polyamine analogs (BE-4-4-4 and BE-4-4-4-4) directly affect growth, survival and cell cycle progression in two human brain tumor cell lines,”Cancer Chemother Pharmacol, 1995, 36, 411-417.
Chen G., et al., “Protection against cyclophosphamide-induced alopecia and inhibition of mammary tumor growth by topical 1,25-dihydroxyvitamin D3in mice,”Int. J. Cancer, 1998, 75, 303-309.
Creaven, P.J., et al., “Unusual central nervous system toxicity in a phase I study of N1N11diethylnorspermine in patients with advanced malignancy,”Invest. New Drugs, 1997, 15, 227-234.
Davis, S.T., et al., “Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors,”Science, Jan. 5, 2001, 291, 134-137.
Desai, M.P., et al., “The mechanism of uptake of biodegradable microparticles in caco-2 cells in size dependent,”Pharm. Res.,1997, 14(11), 1568-1573.
Fuerstein, B.G., et al., “Molecular dynamics of spermine—DNA interactions: sequence specificity and DNA bending for a simple ligand,”Nucl. Acids Res., 1989, 17(17), 6883-6893.
Hahm, H.A., et al., Phase I study of N2N11-diethylnorspermine in patients with non-small cell lung cancer,Clin. Cancer Res., Mar. 2002, 8, 684-690.
Hillery, A.M., et al., “Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60nm polystyrene particles,”J. Drug Targeting, 1994, 2, 151-156.
Ho, D., et al., “Quantitative significance of glutathione and glutathione-S-tranferase in regulating benzo[a]pyreneanti-diol-epoxide level in reconstituted C3H/10T1/2 cell iysates, and comparison to rat liver,”Carcinogenesis, 1984, 5(2), 143-148.
Ho, D., et al., “Modification of glutathione levels in C3H/10T1/2 cells and its relationship to benzo(a)otrebeanti-7,8-dihydrodiol 9,10-expoxide-induced cytotoxicity,”J. Biol. Chem., 1984, 259(18), 11231-11235.
Hussein, A.M., et al., “Protection from chemotherapy-induced alopecia in a rat model,”Science, 1990, 249, 1564-1566.
Jimenez, J.J., et al., “Treatment with ImuVert/Nacetylcysteine protects rats from cyclophosphamide/cytarabine-induced alopecia,”Cancer Investigation, 1992, 10(4), 271-276.
Kramer, D.L.,et al., “Polyamine depletion in human melanoma cells leads to G1arrest associated with induction of p213WAF1/CIP1/SD11, changes in the expression of p21-regulated genes, and a senescence-like phenotype,”Cancer Res., 2001, 61, 7754-7762.
Masuda, K., et al., “Response of previously irradiated mouse skin to a second course of irradiation: early skin reaction and skin shrinkage,”Int. J. Radiation Oncol. Biol. Phys., 1986, 12, 1645-1651.
Morgan, D.M.L., “Polyamines—an overview,”Molecular Biotechnology, 1999, 11, 229-250.
Reddy, et al., “Cis-Unsaturated analogues of 3,8,13,18,23-pentaazapentacosane (BE-4-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cell lines,”J. med. Chem., 2001, 44, 404-417.
Reddy, et al., “Conformationally restricted analogues of1N,12N-bisethylspemine: synthesis and growth inhibitory effects on human tumor cell lines,”J. Med. Chem., 1998, 41, 4723-4732.
Saminathan, M., et al., “Ionic and structural specificity effects of natural and synthetic polyamines on the aggregation and resolubilization of single-, and triple-stranded DNA,”Biochemistry, 1999, 38, 3821-3830.
Sonis, S.T., et al., “Defining mechanisms of action of interleukin-11 on the progression of radiation-induced of oral mucositis in hamsters,”Oral Oncology, 2000, 36, 373-381.
Spotheim-Maurizot, M., et al., “Radioprotection of DNA by polyamines,”Int. J. Radiant, Biol., 1995, 68(5), 571-577.
Streiff, R.R., et al., “Phase 1 study of N1N11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies,”Invest. New Drugs, 2001, 19, 29-39.
Valasinas, et al., “Conformationally restricted analogues of1N,14N-bisethylhomospemine (BE-4-4-4): synthesis and growth inhibitory effects on human prostate cancer cells,”J. Med. Chem., 2001, 44, 390-403.
U.S. Appl. No. 09/565,714, filed May 5, 2001, Fahl et al.
PCT International Search Report dated Dec. 20, 2002 (PCT/US02/25216).
Fahl William E.
Kink John
Weddington Kevin E.
Wisconsin Alumni Research Foundation
Woodcock & Washburn LLP
LandOfFree
Polyamines and analogs for protecting cells during cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polyamines and analogs for protecting cells during cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polyamines and analogs for protecting cells during cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3622638